Invest in Ventoux Biosciences

On a mission to revolutionize treatment for Dupuytren's disease.

Exclusive
Friends Invest First
Public Launch on Apr 30 @ 9:00 AM ET
--
day
--
hour
--
min
--
sec
INVESTMENT TERMS
Future Equity
 $6M  $5.4M valuation cap
Early Bird Bonus: The first $100K of investments will be in a SAFE with a $5.4M valuation cap
$250, $500, $1K, $10K

Highlights

1
Dupuytren's impacts >40m patients in US and Europe and global disease market size est. at USD $4.3B
2
Completed in vivo mouse study, achieved anti-fibrotic effects with lead candidate (VEN-201)
3
Advancing lead candidate (VEN-201) to initial FDA meeting and formulation optimization
4
Currently, no approved pharmacologic treatment options to slow / delay progression of Dupuytren's

Our Team


On a mission to deliver novel, first-line, disease modifying therapies for Dupuytren's disease.
























Downloads

Overview